Matt Coelho

@mattcoelho.bsky.social

Cancer Research UK Career Development Fellow at the Wellcome Sanger Institute - gene editing - drug resistance - cancer

Our paper on genetic mediators of cancer cell susceptibility to T cell killing is out today online: www.cell.com/cell-reports... These genes could serve as biomarkers of sensitivity to immunotherapy - they modulate IFN-g and TNF-a response and are lost in some tumours Thread below on our preprint👇

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

Immunotherapies only provide benefit for a subset of individuals with cancer, highlighting the need for biomarkers of response. Using whole-genome CRISPR-Cas9 screens, Watterson et al. map genetic dep...

cell.com

Matt Coelho@mattcoelho.bsky.social · last yr.

Excited to announce our preprint today @biorxivpreprint.bsky.social Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells: www.biorxiv.org/content/10.1...

New biomarkers for cancer immunotherapy have been identified. 🔎 Researchers found that loss of two genes, CHD1 and MAP3K7, makes tumours more likely to respond to immunotherapy. The findings could help support more personalised cancer treatment 👇 bit.ly/4sMBTq2

Immunotherapy success could be predicted with new biomarkers

Scientists pinpoint two cancer genes that when deleted, improve the vulnerability of tumour cells to immunotherapy.

bit.ly

Looking to start your lab in generative biology / AI? Come join us at the @sangerinstitute.bsky.social Sanger is core-funded so you can generate data at scale to train the next generation of models and understanding. Design/Engineering/Chemistry/Proteins/Pathways! pls RT tinyurl.com/GenGenFaculty

Group Leader - Generative Biology and AI

Do you want to help us improve human health and understand life on Earth? Make your mark by shaping the future to enable or deliver life-changing science to solve some of humanity’s greatest challenge...

tinyurl.com

WRN inhibitors are being tested in patients with MSI cancers. How do tumours adapt to WRN inhibition, and can therapy stay ahead of resistance? Our latest preprint investigates how MSI tumours evolve under pressure from WRN inhibition. Highlights below.